## **Supplementary Information**





Figure S1. Evaluation of IC50 of the indicated compounds using mouse myoblasts.









Figure S2. Evaluation of EC50 of the indicated compounds using mouse myoblasts.



**Figure S3**. Graphs obtained after evaluation exon skipping efficiency of the control Vs the AOs using a two-factor variance analysis.